Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Phase 2 Interventional Results available

Neo-Adjuvant FOLFOX for Rectal Carcinoma

NCT00832299
Conditions
Rectal Neoplasms
Interventions
FOLFOX, total mesorectal excision (TME)
Drug · Procedure
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
New York, New York
Conditions
Melanoma
Interventions
Pimonidazole
Drug
Lead sponsor
Yana Najjar
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Rectal Cancer
Interventions
Short Course Radiation Therapy (scRT), Total Mesenteric Excision (TME)
Radiation · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Chicago, Illinois • New Brunswick, New Jersey • Brooklyn, New York + 1 more
Conditions
Rectal Cancer
Interventions
TaTME, TME
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Radiation Therapy, Sigmoidoscopy, Total Mesorectal Excision
Procedure · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
213
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 145 more
Conditions
Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
Interventions
Retifanlimab, Gemcitabine, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Not applicable Interventional

Multicenter Phase II Study of Transanal TME (taTME)

NCT03144765
Conditions
Rectal Cancer, Surgery
Interventions
Transanal Total Mesorectal Excision (taTME)
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Orlando, Florida + 6 more
Conditions
Advanced Solid Tumor
Interventions
Nemvaleukin alfa, Pembrolizumab
Biological
Lead sponsor
Mural Oncology, Inc
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Grand Rapids, Michigan • Houston, Texas • West Valley City, Utah + 1 more
Conditions
Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin, Oxaliplatin, Quality-of-Life Assessment, Surveillance, Total Mesorectal Excision
Drug · Radiation · Other + 2 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Recurrent Prostate Cancer
Interventions
Biopsy
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Locally Advanced Rectal Adenocarcinoma
Interventions
APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Tucson, Arizona • Winston-Salem, North Carolina • Portland, Oregon + 1 more
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Consolidation Therapy, Functional Magnetic Resonance Imaging, Gastrointestinal Endoscopy, Magnetic Resonance Imaging, Papaverine, Radiation Therapy, Total Mesorectal Excision
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Conditions
Advanced Solid Tumor
Interventions
SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 5 more
Conditions
Recurrent Ovarian Cancer
Interventions
CPI-0209, carboplatin
Drug
Lead sponsor
Lan Coffman
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Stage II Rectal Cancer, Stage III Rectal Cancer
Interventions
Capecitabine, 5-FU, Leucovorin, Oxaliplatin, radiation, total mesorectal excision
Drug · Radiation · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Rectal Cancer
Interventions
FOLFOXIRI, FOLFOX regimen, XELOX, IMRT
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Conditions
Severe Combined Immunodeficiency, Transplacental Maternal Engraftment, Stem Cell Transplant
Interventions
Sirolimus
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Day to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Conditions
Rectal Cancer
Interventions
M1 scheme, standard long course chemoradiotherapy
Other
Lead sponsor
University Medical Center Groningen
Other
Eligibility
18 Years and older
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Not listed No phase listed Observational

TME Neoadjuvant Breast Registry

NCT02596724
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Genomic and/or molecular testing of blood or tissue
Other
Lead sponsor
Targeted Medical Education
Other
Eligibility
18 Years to 90 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Los Gatos, California • Allentown, Pennsylvania • Nashville, Tennessee + 1 more
Conditions
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions
azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland